|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||187.82 - 190.39|
|52 Week Range||114.27 - 194.61|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.96 (1.54%)|
|Ex-Dividend Date||Nov 11, 2019|
|1y Target Est||N/A|
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc ...
Shares of AbbVie Inc. and Allergan plc were both up about 1% in trading on Wednesday after AbbVie announced new plans for the combined company once the pending $63 billion acquisition of Allergan closes. It's the first time the company has shared leadership plans since confirming that Richard Gonzalez would stay in his role as CEO of AbbVie. Allergan CEO Brent Saunders will be on the board of directors but does not have a role in the combined company, according to an AbbVie spokeswoman. One Allergan executive, Carrie Strom, will join the executive leadership team of the combined company; the other eight members are AbbVie executives. Strom will lead the newly created Allergan Aesthetics, a separate Irvine, Calif.-based business for Botox and the other Allergan medical aesthetics treatments. It will also conduct its own research and development. Allergan's other therapies, including Botox for indications other than aesthetics, the antipsychotic Vraylar and irritable bowel syndrome drug Linzess, will be folded into AbbVie, which is based in North Chicago. The deal is expected to close this quarter. Over the last year, Allergan's stock is up 31%, and AbbVie's stock is down 1%. The S&P 500 has gained 27% over the last 52 weeks.
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump's airstrike killed Iran's top military commander.
Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases are below 10%, with the median price increase around 5%, according to 3 Axis. Swiss drugmaker Novartis raised prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya, 3 Axis said.
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Shares of Allergan gained 0.5% after the Food and Drug Administration approved Ubrelvy, its migraine treatment. In two late-stage clinical trials, more patients who were taking the experimental therapy reported the pain ending within two hours compared to those taking the placebo. Allergan's neurology pipeline, which includes Ubrelvy, has been a key area of focus for the company, according to SVB Leerink's Geoffrey Porges in a July note. Earlier this year, the regulator approved Eli Lilly's migraine treatment Reyvow. Allergan's stock is up 43% year-to-date, while the S&P 500 has gained 28%.
Allergan execs tell TheStreet just how the company will diversify its product mix, but it still plans to sell Botox in volume.
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.